Drug discovery
12
drugs
With orphan designations
Overview
Achondroplasia is a genetic disorder caused by FGFR3 gene mutations, resulting in impaired endochondral ossification and disproportionate short stature (rhizomelic shortening). Key features include spinal stenosis, recurrent otitis media, sleep apnea, and orthopedic complications. Management involves multispecialty monitoring, surgical interventions for spinal/limb deformities, and emerging pharmacotherapies targeting FGFR3 pathways [1][6][8]. Most patients have normal intelligence and lifespan with proactive care [1][11].
Burden
Lifetime complications: 80% develop spinal stenosis by age 60; 20–50% experience neurological deficits [6][9][17].
Healthcare costs: Hospitalizations average $19,959/admission (35% above U.S. mean), driven by neonatal care and musculoskeletal surgeries [17].
Psychosocial impact: Reduced quality of life, emotional distress, and functional limitations due to chronic pain/disproportionate anatomy [4][5].
Therapies
Surgical: Limb lengthening (up to 30–40 cm total), spinal decompression, and guided growth procedures [3][8][17].
Pharmacologic: Vosoritide (FDA-approved CNP analog) improves growth velocity; investigational agents include TransCon CNP and FGFR3 inhibitors [4][5][13].
Supportive: Physical/occupational therapy, weight management, and polysomnography for sleep apnea [6][8].
Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases
Drug Discovery Landscape
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
selective small molecular inhibitor of fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) | small molecules | FDA | 2026-03-16 | — | Abbisko Therapeutics Co., Ltd. |
Small molecule fibroblast growth factor receptor 3 selective tyrosine kinase inhibitor | small molecules | FDA | 2023-07-25 | — | Tyra Biosciences |
Anti-fibroblast growth factor receptor 3 antigen-binding fragment (anti-FGFR3 Fab) | antibodies | FDA | 2022-01-25 | — | Genzyme Corporation, a Sanofi Company |
Infigratinib | small molecules | FDA | 2021-08-12 | — | QED Therapeutics, Inc. |
Infigratinib | small molecules | EMA | 2021-07-19 | — | BridgeBio Pharma Europe B.V. |
Humanised monoclonal antibody derivative against fibroblast growth factor receptor 3 | antibodies | EMA | 2021-06-21 | — | Sanofi B.V. |
C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker | proteins | EMA | 2020-07-27 | — | Ascendis Pharma Growth Disorders A/S |
navepegritide [Yuviwel] | proteins | FDA | 2019-02-27 | 2026-02-27 | Ascendis Pharma Growth Disorders A/S |
Recombinant human fibroblast growth factor receptor 3 | proteins | FDA | 2017-06-02 | — | Pfizer Inc. |
Recifercept | proteins | EMA | 2017-02-27 | — | Pfizer Europe MA EEIG |
Modified recombinant human C-type natriuretic peptide [Voxzogo] | proteins | EMA | 2013-01-24 | 2021-09-01 | BioMarin International Limited |
vosoritide [Voxzogo] | peptides | FDA | 2013-01-17 | 2021-11-19 | BioMarin Pharmaceutical, Inc. |